ctla4 ig fusion protein Search Results


fusion protein ctla4-ig  (Rosetta Inpharmatics)
90
Rosetta Inpharmatics fusion protein ctla4-ig
Fusion Protein Ctla4 Ig, supplied by Rosetta Inpharmatics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fusion protein ctla4-ig/product/Rosetta Inpharmatics
Average 90 stars, based on 1 article reviews
fusion protein ctla4-ig - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
cd152 (ctla-4) (mouse) ig fusion protein  (Enzo Biochem)
90
Enzo Biochem cd152 (ctla-4) (mouse) ig fusion protein
Cd152 (Ctla 4) (Mouse) Ig Fusion Protein, supplied by Enzo Biochem, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd152 (ctla-4) (mouse) ig fusion protein/product/Enzo Biochem
Average 90 stars, based on 1 article reviews
cd152 (ctla-4) (mouse) ig fusion protein - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
fusion protein ctla-4-ig  (Glaxo Smith)
90
Glaxo Smith fusion protein ctla-4-ig
Fusion Protein Ctla 4 Ig, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/fusion protein ctla-4-ig/product/Glaxo Smith
Average 90 stars, based on 1 article reviews
fusion protein ctla-4-ig - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
mutant ctla-4–ig fusion proteins  (Syd Labs)
90
Syd Labs mutant ctla-4–ig fusion proteins
(A to D) Data shown are OD450 values from an ELISA using plates coated with indicated <t>CTLA-4–Ig</t> fusion proteins (1 μg/ml) and detected with the given concentration (Con.; 0 to 100 μg/ml) of biotinylated hB7-1Fc (A), hB7-2Fc (B), ipilimumab (C) or Treme-IgG1 (D). (E to G) Data shown are OD450 values from an ELISA using plates coated with indicated M17 mutations (1 μg/ml) and detected by the given concentration of biotinylated hB7-1Fc (E), ipilimumab (F), or Treme-IgG1 (G). (H) Anti-CD3/CD28 mAb-activated human PBMCs were incubated with Alexa Fluor 488 (AF488)–conjugated ipilimumab in the presence of the given dose of CTLA-4–Ig or hIgFc. Representative flow cytometry histograms (fusion protein at 10 μg/ml; left) and quantitative mean fluorescence intensity (MFI) of AF488 (right) are shown. (I) hCTLA-4–Y201V–expressing cells were incubated with biotinylated hB7-1 or hB7-2 in the presence of the given dose of CTLA-4–Ig or hIgFc and detected by streptavidin-PE. (J) hB7-1–or hB7-2–expressing CHO cells were incubated with biotinylated hCD28 in the presence of the given dose of CTLA-4-Ig or hIgFc and detected by streptavidin-PE. (K and L) The ability of CTLA-4–Ig to block B7 trans-endocytosis by CTLA-4 was measured. CHO cells transfected with hCTLA-4–OFP and hB7-1–GFP (K) or B7-2–GFP (L) were cocultured in the presence of serial dilutions of CTLA-4–Ig or hIgFc for 4 hours at 37°C. Representative flow cytometry plots (left) and percentage of trans-endocytosis (right) are shown. Data are representative of at least two independent experiments.
Mutant Ctla 4–Ig Fusion Proteins, supplied by Syd Labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mutant ctla-4–ig fusion proteins/product/Syd Labs
Average 90 stars, based on 1 article reviews
mutant ctla-4–ig fusion proteins - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti-ctla4  (Future Medicine Ltd)
90
Future Medicine Ltd anti-ctla4
(A to D) Data shown are OD450 values from an ELISA using plates coated with indicated <t>CTLA-4–Ig</t> fusion proteins (1 μg/ml) and detected with the given concentration (Con.; 0 to 100 μg/ml) of biotinylated hB7-1Fc (A), hB7-2Fc (B), ipilimumab (C) or Treme-IgG1 (D). (E to G) Data shown are OD450 values from an ELISA using plates coated with indicated M17 mutations (1 μg/ml) and detected by the given concentration of biotinylated hB7-1Fc (E), ipilimumab (F), or Treme-IgG1 (G). (H) Anti-CD3/CD28 mAb-activated human PBMCs were incubated with Alexa Fluor 488 (AF488)–conjugated ipilimumab in the presence of the given dose of CTLA-4–Ig or hIgFc. Representative flow cytometry histograms (fusion protein at 10 μg/ml; left) and quantitative mean fluorescence intensity (MFI) of AF488 (right) are shown. (I) hCTLA-4–Y201V–expressing cells were incubated with biotinylated hB7-1 or hB7-2 in the presence of the given dose of CTLA-4–Ig or hIgFc and detected by streptavidin-PE. (J) hB7-1–or hB7-2–expressing CHO cells were incubated with biotinylated hCD28 in the presence of the given dose of CTLA-4-Ig or hIgFc and detected by streptavidin-PE. (K and L) The ability of CTLA-4–Ig to block B7 trans-endocytosis by CTLA-4 was measured. CHO cells transfected with hCTLA-4–OFP and hB7-1–GFP (K) or B7-2–GFP (L) were cocultured in the presence of serial dilutions of CTLA-4–Ig or hIgFc for 4 hours at 37°C. Representative flow cytometry plots (left) and percentage of trans-endocytosis (right) are shown. Data are representative of at least two independent experiments.
Anti Ctla4, supplied by Future Medicine Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-ctla4/product/Future Medicine Ltd
Average 90 stars, based on 1 article reviews
anti-ctla4 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
ctla-4 fusion protein (ctla-4 ig/ abatacept)  (Clinisciences)
90
Clinisciences ctla-4 fusion protein (ctla-4 ig/ abatacept)
(A to D) Data shown are OD450 values from an ELISA using plates coated with indicated <t>CTLA-4–Ig</t> fusion proteins (1 μg/ml) and detected with the given concentration (Con.; 0 to 100 μg/ml) of biotinylated hB7-1Fc (A), hB7-2Fc (B), ipilimumab (C) or Treme-IgG1 (D). (E to G) Data shown are OD450 values from an ELISA using plates coated with indicated M17 mutations (1 μg/ml) and detected by the given concentration of biotinylated hB7-1Fc (E), ipilimumab (F), or Treme-IgG1 (G). (H) Anti-CD3/CD28 mAb-activated human PBMCs were incubated with Alexa Fluor 488 (AF488)–conjugated ipilimumab in the presence of the given dose of CTLA-4–Ig or hIgFc. Representative flow cytometry histograms (fusion protein at 10 μg/ml; left) and quantitative mean fluorescence intensity (MFI) of AF488 (right) are shown. (I) hCTLA-4–Y201V–expressing cells were incubated with biotinylated hB7-1 or hB7-2 in the presence of the given dose of CTLA-4–Ig or hIgFc and detected by streptavidin-PE. (J) hB7-1–or hB7-2–expressing CHO cells were incubated with biotinylated hCD28 in the presence of the given dose of CTLA-4-Ig or hIgFc and detected by streptavidin-PE. (K and L) The ability of CTLA-4–Ig to block B7 trans-endocytosis by CTLA-4 was measured. CHO cells transfected with hCTLA-4–OFP and hB7-1–GFP (K) or B7-2–GFP (L) were cocultured in the presence of serial dilutions of CTLA-4–Ig or hIgFc for 4 hours at 37°C. Representative flow cytometry plots (left) and percentage of trans-endocytosis (right) are shown. Data are representative of at least two independent experiments.
Ctla 4 Fusion Protein (Ctla 4 Ig/ Abatacept), supplied by Clinisciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ctla-4 fusion protein (ctla-4 ig/ abatacept)/product/Clinisciences
Average 90 stars, based on 1 article reviews
ctla-4 fusion protein (ctla-4 ig/ abatacept) - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


(A to D) Data shown are OD450 values from an ELISA using plates coated with indicated CTLA-4–Ig fusion proteins (1 μg/ml) and detected with the given concentration (Con.; 0 to 100 μg/ml) of biotinylated hB7-1Fc (A), hB7-2Fc (B), ipilimumab (C) or Treme-IgG1 (D). (E to G) Data shown are OD450 values from an ELISA using plates coated with indicated M17 mutations (1 μg/ml) and detected by the given concentration of biotinylated hB7-1Fc (E), ipilimumab (F), or Treme-IgG1 (G). (H) Anti-CD3/CD28 mAb-activated human PBMCs were incubated with Alexa Fluor 488 (AF488)–conjugated ipilimumab in the presence of the given dose of CTLA-4–Ig or hIgFc. Representative flow cytometry histograms (fusion protein at 10 μg/ml; left) and quantitative mean fluorescence intensity (MFI) of AF488 (right) are shown. (I) hCTLA-4–Y201V–expressing cells were incubated with biotinylated hB7-1 or hB7-2 in the presence of the given dose of CTLA-4–Ig or hIgFc and detected by streptavidin-PE. (J) hB7-1–or hB7-2–expressing CHO cells were incubated with biotinylated hCD28 in the presence of the given dose of CTLA-4-Ig or hIgFc and detected by streptavidin-PE. (K and L) The ability of CTLA-4–Ig to block B7 trans-endocytosis by CTLA-4 was measured. CHO cells transfected with hCTLA-4–OFP and hB7-1–GFP (K) or B7-2–GFP (L) were cocultured in the presence of serial dilutions of CTLA-4–Ig or hIgFc for 4 hours at 37°C. Representative flow cytometry plots (left) and percentage of trans-endocytosis (right) are shown. Data are representative of at least two independent experiments.

Journal: Science translational medicine

Article Title: Soluble CTLA-4 mutants ameliorate immune-related adverse events but preserve efficacy of CTLA-4– and PD-1–targeted immunotherapy

doi: 10.1126/scitranslmed.abm5663

Figure Lengend Snippet: (A to D) Data shown are OD450 values from an ELISA using plates coated with indicated CTLA-4–Ig fusion proteins (1 μg/ml) and detected with the given concentration (Con.; 0 to 100 μg/ml) of biotinylated hB7-1Fc (A), hB7-2Fc (B), ipilimumab (C) or Treme-IgG1 (D). (E to G) Data shown are OD450 values from an ELISA using plates coated with indicated M17 mutations (1 μg/ml) and detected by the given concentration of biotinylated hB7-1Fc (E), ipilimumab (F), or Treme-IgG1 (G). (H) Anti-CD3/CD28 mAb-activated human PBMCs were incubated with Alexa Fluor 488 (AF488)–conjugated ipilimumab in the presence of the given dose of CTLA-4–Ig or hIgFc. Representative flow cytometry histograms (fusion protein at 10 μg/ml; left) and quantitative mean fluorescence intensity (MFI) of AF488 (right) are shown. (I) hCTLA-4–Y201V–expressing cells were incubated with biotinylated hB7-1 or hB7-2 in the presence of the given dose of CTLA-4–Ig or hIgFc and detected by streptavidin-PE. (J) hB7-1–or hB7-2–expressing CHO cells were incubated with biotinylated hCD28 in the presence of the given dose of CTLA-4-Ig or hIgFc and detected by streptavidin-PE. (K and L) The ability of CTLA-4–Ig to block B7 trans-endocytosis by CTLA-4 was measured. CHO cells transfected with hCTLA-4–OFP and hB7-1–GFP (K) or B7-2–GFP (L) were cocultured in the presence of serial dilutions of CTLA-4–Ig or hIgFc for 4 hours at 37°C. Representative flow cytometry plots (left) and percentage of trans-endocytosis (right) are shown. Data are representative of at least two independent experiments.

Article Snippet: Antibodies and reagents All mutant CTLA-4–Ig fusion proteins were generated by Sydlabs Inc. by transient expression in the 293 cell line.

Techniques: Enzyme-linked Immunosorbent Assay, Concentration Assay, Incubation, Flow Cytometry, Fluorescence, Expressing, Blocking Assay, Transfection